The test’s rapid diagnostic capabilities are crucial for managing respiratory infections with similar symptoms. Credit: angellodeco/Shutterstock.com.

DCN Dx, a contract research organisation for in vitro diagnostics, has announced that Wondfo USA’s WELLlife Covid-19/Influenza A&B Test received emergency use authorisation (EUA) from the US Food and Drug Administration (FDA).

Wondfo USA’s collaboration with DCN Dx through the National Institutes of Health (NIH) Independent Test Assessment Program (ITAP) has led to the performance and clinical validation of the WELLlife test in the US.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

DCN Dx chief operating officer Pat Vaughan said: “We extend our congratulations to the Wondfo USA team on achieving FDA EUA for the WELLlife test. Their dedication and expertise have culminated in a crucial tool that will positively impact healthcare.”

The authorisation allows healthcare providers to quickly distinguish between Covid-19 and influenza, improving patient outcomes at the point of care.

The test’s rapid diagnostic capabilities are crucial for managing respiratory infections with similar symptoms.

See Also:

DCN Dx said the NIH’s Rapid Acceleration of Diagnostics (RADx) Tech programme and its ITAP have been instrumental in expediting the regulatory review and availability of high-quality diagnostic tests.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Wondfo USA’s WELLlife test is designed to allow the qualitative detection and differentiation of influenzas A and B, as well as SARS-CoV-2, from anterior nasal samples.

The rapid diagnostic test is a critical tool for healthcare professionals to manage and treat respiratory virus infections, which often have overlapping clinical presentations.

DCN Dx clinical research vice-president Emily Friedland said: “Our role in the clinical research for the WELLlife test exemplifies our commitment to supporting the development and commercialisation of important diagnostics.

“We are proud to have supported Wondfo USA in the clinical research and validation stages that were crucial for achieving FDA EUA.”